Latest Breaking News On - அறிவியல் குழு ஆன் மருந்துகள் - Page 1 : comparemela.com
Awakn Life Sciences Corp : Awakn Life Sciences Appoints Addiction Expert Prof David Nutt as Chief Research Officer
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Awakn Life Sciences Appoints Addiction Expert Prof David Nutt as Chief Research Officer
investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.
Почему полный отказ от алкоголя может нанести вред
comandir.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from comandir.com Daily Mail and Mail on Sunday newspapers.
Марш в Киеве сегодня онлайн - митинг националистов в вышиванках в честь дивизии СС Галичина
strana.ua - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from strana.ua Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic .
Algernon PharmaceuticalsFebruary 1, 2021 GMT
VANCOUVER, British Columbia, Feb. 01, 2021 (GLOBE NEWSWIRE) Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that it has established a clinical research program for the treatment of stroke focused on AP-188 (“N,N-Dimethyltryptamine or DMT”), a known psychedelic compound that is part of the tryptamine family (other drugs in the tryptamine family include psilocybin and psilocin). Algernon plans to be the first company globally to pursue DMT for stroke in humans and is planning to begin a clinical trial as soon as possible in 2021.